Praxis Precision Medicines Inc (PRAX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Praxis Precision Medicines Inc stock (PRAX) is currently trading at $311.92. Praxis Precision Medicines Inc PS ratio (Price-to-Sales) is 953.14. Analyst consensus price target for PRAX is $617.62. WallStSmart rates PRAX as Sell.
- PRAX PE ratio analysis and historical PE chart
- PRAX PS ratio (Price-to-Sales) history and trend
- PRAX intrinsic value — DCF, Graham Number, EPV models
- PRAX stock price prediction 2025 2026 2027 2028 2029 2030
- PRAX fair value vs current price
- PRAX insider transactions and insider buying
- Is PRAX undervalued or overvalued?
- Praxis Precision Medicines Inc financial analysis — revenue, earnings, cash flow
- PRAX Piotroski F-Score and Altman Z-Score
- PRAX analyst price target and Smart Rating
Praxis Precision Medicines Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Praxis Precision Medicines Inc (PRAX) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and price/sales. Significant fundamental concerns warrant caution or avoidance.
Praxis Precision Medicines Inc (PRAX) Key Strengths (3)
Revenue surging 1349.00% year-over-year
107.22% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Praxis Precision Medicines Inc (PRAX) Areas to Watch (3)
Company is destroying shareholder value
Very expensive at 953.1x annual revenue
Very expensive at 9.5x book value
Supporting Valuation Data
Praxis Precision Medicines Inc (PRAX) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 3 register as strengths (avg 9.0/10) while 3 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Growth metrics are encouraging with Revenue Growth at 1349.00%.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Price/Book. Some valuation metrics including Price/Sales (953.14), Price/Book (9.46) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -45.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -45.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 1349.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PRAX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PRAX's Price-to-Sales ratio of 953.14x trades 105% above its historical average of 464.51x (78th percentile), historically expensive. The current valuation is 13% below its historical high of 1092.14x set in Feb 2026, and 6117% above its historical low of 15.33x in Mar 2023. Over the past 12 months, the PS ratio has expanded from ~125.4x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Praxis Precision Medicines Inc (PRAX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Praxis Precision Medicines Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 7M with 1349% growth year-over-year.
Key Findings
Revenue growing at 1349% YoY, reaching 7M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 1039% of revenue (78M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -77M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Praxis Precision Medicines Inc maintain 1349%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 3.01, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Praxis Precision Medicines Inc.
Bottom Line
Praxis Precision Medicines Inc is a high-conviction growth story with revenue accelerating at 1349% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Praxis Precision Medicines Inc(PRAX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. The company is headquartered in Cambridge, Massachusetts.